<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) secondary to myelodysplastic phase respond poorly to standard chemotherapy designed for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>As arabinosyl <z:chebi fb="1" ids="16040">cytosine</z:chebi> (Ara-C) at low-dose has been reported to achieve promising results in certain forms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, we have applied the low-dose (10 mg m-2/12 h subcutaneously for 14-24 days) regimen in 11 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Though a complete remission could be achieved in 2 patients and a short partial remission in 2 further patients, complications are severe and often life threatening </plain></SENT>
<SENT sid="3" pm="."><plain>The amount of hematological supportive care required often exceeded that needed for patients treated by conventional TAD regimen </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, survival of the responders did not seem to be longer than that of non-responders </plain></SENT>
<SENT sid="5" pm="."><plain>A review of the literature showed that the results of this low-dose Ara-C regimen might be more promising in patients in the myelodysplastic phase and in those with de novo <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>